SCIENTIFIC RESEARCH

Our pipeline

Overview

Our focus is developing highly-differentiated, first-in-class or best-in-class precision therapies against validated targets in oncology and other serious diseases.

Oncology

PBI-308 is a potential best-in-class oral small molecule inhibitor targeting disruption of MonoPolar Spindle 1 (Mps1, TTK), a critical protein in cell division that is overexpressed in a variety of tumors.  Inhibition of Mps1 blocks proper cell division through disruption of mitotic spindle assembly, which initiates mitotic catastrophe leading to tumor cell killing. 

Dermatology

In Dermatology, we are developing a clinically-validated, first-in-class, selective TRK modulator, PBI-100, which contains anti-itch, anti-inflammatory and antiproliferative effects. We are developing PBI-100 for a range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis.

Oncology

  • PRECLINICAL
  • IND ENABLING
  • PHASE I
  • PHASE II
PBI-200 - NTRK Fusion Positive Solid Tumors
PBI-308 - Other Solid Tumors
Undisclosed

Dermatology

  • PRECLINICAL
  • IND ENABLING
  • PHASE I
  • PHASE II
PBI-100 - Psoriasis
PBI-100 - Atopic Dermatitis

 

For Clinical Trial Information, Please Visit the Links Below:

 
 
Learn More About Pyramid
Learn More